Status:
COMPLETED
Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
MALE
18-50 years
Phase:
PHASE1
Brief Summary
The primary objective of the current study is to investigate the safety and tolerability of BI 638683 in healthy male volunteers following oral administration of single rising doses
Eligibility Criteria
Inclusion
- Inclusion criteria:
- healthy male subjects
Exclusion
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01195688
Start Date
September 1 2010
Last Update
June 2 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1279.1.1 Boehringer Ingelheim Investigational Site
Biberach, Germany